Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL).
Article in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 6 institutions in 2 countries.
Jae-Cheol JoDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.ORCID http://orcid.org/0000-0001-6014-7977
Jung-Hee LeeDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, Korea.
Sung-Nam LimDepartment of Internal Medicine, Haeundae Paik Hospital, College of Medicine Inje University, Busan, Korea.
Sang Min LeeDepartment of Hematology and Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
Sung-Soo YoonDepartment of Hematology and Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. ssysmc@snu.ac.kr.
In-Ho KimDepartment of Hematology and Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Sung Hwa BaeDepartment of Hematology and Oncology, Daegu Catholic University Hospital, Catholic University of Daegu School of Medicine, Daegu, Korea.
Yoo Jin LeeDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.ORCID http://orcid.org/0000-0001-9106-9326
Yunsuk ChoiDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Won-Sik LeeDepartment of Hematology and Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. wonsik112@gmail.com.
Ulsan College · KRInje University Busan Paik Hospital · KRSeoul National University Hospital · KRDaegu Catholic University · KRInje University Haeundae Paik Hospital · KRSeverance Hospital · KR
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL). · full record | OpenQuestion